Evidence map›Paper›PMID 39071944›Full record

ArticleBone reports2024

Machine learning progressive CKD risk prediction model is associated with CKD-mineral bone disorder.

Joseph Aoki, Omar Khalid, Cihan Kaya, Tarush Kothari, Mark Silberman, Con Skordis, Jonathan Hughes, Jerry Hussong, Mohamed E Salama

Abstract read
In one paragraph

Article in Bone reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joseph AokiSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Omar KhalidSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Cihan KayaSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Tarush KothariSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Mark SilbermanSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Con SkordisSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Jonathan HughesSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Jerry HussongSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.
Mohamed E SalamaSonic Healthcare USA, 12357A - A Riata Trace Parkway, Suite 210, Austin, TX 78727, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recently, we developed the machine learning (ML)-based Progressive CKD Risk Classifier (PCRC), which accurately predicts CKD progression within 5 years. While its performance is robust, it is unknown whether PCRC categorization is associated with CKD-mineral bone disorder (CKD-MBD), a critical, yet under-recognized, downstream consequence. Therefore, we aimed to 1) survey real-world testing utilization data for CKD-MBD and 2) evaluate ML-based PCRC categorization with CKD-MBD. Methods: The cohort study utilized deidentified data from a US laboratory outpatient network, composed of 330,238 outpatients, over 5 years. The main outcomes were: 1) Laboratory testing utilization of eGFR, urine albumin creatinine ratio (UACR), parathyroid hormone (PTH), calcium, phosphate; and 2) PCRC categorization and biochemical abnormalities associated with CKD-MBD over 5 years. Results: We identified significant under-utilization of laboratory testing for UACR, phosphate and PTH, which ranged from -40 % to -100 % against the minimum standard-of-care. At five years, the CKD progression group, as predicted by the PCRC, was associated with 15.5 % increase in phosphate ( Conclusions: We identified significant under-utilization of laboratory testing for CKD-MBD. Moreover, we demonstrated that CKD progression, as predicted by the PCRC, is associated with CKD-MBD, several years in advance of disease. To our knowledge, this investigation is the first to examine the role of predictive analytics for CKD progression on mineral bone disorder. While further studies are required, these findings have the potential to advance AI/ML-based risk stratification and treatment of CKD and CKD-MBD.

Indexed as

CalciumChronic kidney diseaseChronic kidney disease-metabolic bone disorderMachine learningParathyroid hormonePhosphate

Identifiers

PMID39071944
PMCPMC11277315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.